278 related articles for article (PubMed ID: 33721148)
61. Bone marrow micrometastases and adjuvant treatment of breast cancer.
Yu JJ; Brennan M; Christos P; Osborne MP; Hoda S; Simmons RM
Breast J; 2004; 10(3):181-5. PubMed ID: 15125741
[TBL] [Abstract][Full Text] [Related]
62. [Clinical features and prognostic factors of small breast cancer with multiple axillary lymph node metastasis].
Liao YQ; Xu BH
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):615-8. PubMed ID: 18210884
[TBL] [Abstract][Full Text] [Related]
63. Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients?
Sávolt A; Polgár C; Musonda P; Mátrai Z; Rényi-Vámos F; Tóth L; Kásler M; Péley G
Clin Breast Cancer; 2013 Oct; 13(5):364-70. PubMed ID: 23773380
[TBL] [Abstract][Full Text] [Related]
64. Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?
Galimberti V; Botteri E; Chifu C; Gentilini O; Luini A; Intra M; Baratella P; Sargenti M; Zurrida S; Veronesi P; Rotmensz N; Viale G; Sonzogni A; Colleoni M; Veronesi U
Breast Cancer Res Treat; 2012 Feb; 131(3):819-25. PubMed ID: 21468637
[TBL] [Abstract][Full Text] [Related]
65. Prognosis of node-positive breast cancer patients who underwent parasternal lymph node biopsy during surgery followed by doxorubicin- or mitoxantrone-containing adjuvant chemotherapy.
Kanno M; Nakamura S; Uotani C; Yamanaka S; Terasaki Y; Tsugawa K; Noguchi M
J Chemother; 2000 Oct; 12(5):435-41. PubMed ID: 11128565
[TBL] [Abstract][Full Text] [Related]
66. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes.
van Rijk MC; Peterse JL; Nieweg OE; Oldenburg HS; Rutgers EJ; Kroon BB
Cancer; 2006 Aug; 107(3):467-71. PubMed ID: 16804924
[TBL] [Abstract][Full Text] [Related]
67. The clinical significance of axillary lymph node micrometastases in breast cancer.
Sakorafas GH; Geraghty J; Pavlakis G
Eur J Surg Oncol; 2004 Oct; 30(8):807-16. PubMed ID: 15336724
[TBL] [Abstract][Full Text] [Related]
68. Management and results of treatment of breast cancer patients having sentinel lymph node micrometastases.
Nowikiewicz T; Srutek E; Jankowski M; Las-Jankowska M; Klag M; Kozak D; Glowacka I; Zegarski W
Neoplasma; 2014; 61(3):299-304. PubMed ID: 24824931
[TBL] [Abstract][Full Text] [Related]
69. Influence of internal mammary node irradiation on long-term outcome and contralateral breast cancer incidence in node-negative breast cancer patients.
Courdi A; Chamorey E; Ferrero JM; Hannoun-Lévi JM
Radiother Oncol; 2013 Aug; 108(2):259-65. PubMed ID: 23891092
[TBL] [Abstract][Full Text] [Related]
70. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry.
Chagpar A; Middleton LP; Sahin AA; Meric-Bernstam F; Kuerer HM; Feig BW; Ross MI; Ames FC; Singletary SE; Buchholz TA; Valero V; Hunt KK
Cancer; 2005 Apr; 103(8):1581-6. PubMed ID: 15747375
[TBL] [Abstract][Full Text] [Related]
71. Axillary recurrence rate after tumour negative and micrometastatic positive sentinel node procedures in breast cancer patients, a population based multicenter study.
Bulte CS; van der Heiden-van der Loo M; Hennipman A
Eur J Surg Oncol; 2009 Jan; 35(1):25-31. PubMed ID: 18640809
[TBL] [Abstract][Full Text] [Related]
72. Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer.
Mamtani A; Patil S; Stempel M; Morrow M
Ann Surg Oncol; 2017 Aug; 24(8):2182-2188. PubMed ID: 28429197
[TBL] [Abstract][Full Text] [Related]
73. [Clinical significance of sentinel lymph node micrometastases in invasive breast carcinoma].
Tsugawa K
Nihon Geka Gakkai Zasshi; 2013 Jan; 114(1):22-7. PubMed ID: 23457941
[TBL] [Abstract][Full Text] [Related]
74. [A new perspective on axillary dissection in situations of metastatic sentinel node].
Zedníková I; Ňaršanská A; Hes O; Metelková A; Fiala O; Svoboda T
Rozhl Chir; 2017; 96(8):346-352. PubMed ID: 29058925
[TBL] [Abstract][Full Text] [Related]
75. Evaluation of immunohistochemistry and multiple-level sectioning in sentinel lymph nodes from patients with breast cancer.
Pargaonkar AS; Beissner RS; Snyder S; Speights VO
Arch Pathol Lab Med; 2003 Jun; 127(6):701-5. PubMed ID: 12741893
[TBL] [Abstract][Full Text] [Related]
76. Pathologic Evaluation and Prognostic Implications of Nodal Micrometastases in Breast Cancer.
Dutta SW; Volaric A; Morgan JT; Chinn Z; Atkins KA; Janowski EM
Semin Radiat Oncol; 2019 Apr; 29(2):102-110. PubMed ID: 30827448
[TBL] [Abstract][Full Text] [Related]
77. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection.
Kamath VJ; Giuliano R; Dauway EL; Cantor A; Berman C; Ku NN; Cox CE; Reintgen DS
Arch Surg; 2001 Jun; 136(6):688-92. PubMed ID: 11387010
[TBL] [Abstract][Full Text] [Related]
78. Clinical axillary recurrence in breast cancer patients after a negative sentinel node biopsy.
Chung MA; Steinhoff MM; Cady B
Am J Surg; 2002 Oct; 184(4):310-4. PubMed ID: 12383890
[TBL] [Abstract][Full Text] [Related]
79. Clinical implications of axillary sentinel lymph node 'micrometastases' in breast cancer.
Krauth JS; Charitansky H; Isaac S; Bobin JY
Eur J Surg Oncol; 2006 May; 32(4):400-4. PubMed ID: 16504456
[TBL] [Abstract][Full Text] [Related]
80. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study.
Reed J; Rosman M; Verbanac KM; Mannie A; Cheng Z; Tafra L
J Am Coll Surg; 2009 Mar; 208(3):333-40. PubMed ID: 19317993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
